gastric juice protein is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Quality assessment rests on two separate questions: whether the chain is the intended one, and how much of the sample is that chain. Reverse-phase high-performance liquid chromatography with ultraviolet detection is the standard purity measurement, while mass spectrometry confirms identity through the observed molecular mass. Amino acid analysis and sequence verification provide further checks. A reported purity percentage describes the proportion of the sample represented by the main peak, not the amount of peptide by mass, since counter-ions and water make up part of any lyophilized lot.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried cake or loose powder after lyophilization |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are less durable than the powder |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light; avoid repeated freeze-thaw cycles |
| Identity method | Electrospray mass spectrometry | Compared against the expected mass; paired with sequence or composition analysis |
| Purity method | Reverse-phase HPLC with ultraviolet detection | Reports main-peak percentage rather than peptide content by mass |
Material of this kind is sold for laboratory research, and labels typically state that it is not intended for human or veterinary use. In many countries it is not an approved medicine, and sports antidoping rules place it among prohibited non-approved substances. Buyers commonly review a certificate of analysis, an independent test report, and the declared storage conditions. Batch-to-batch variation in purity and in counterion content is possible, and how much that variation affects experimental outcomes remains an open question.
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
In 1914, The New York Times published an article titled "Negro Cocaine 'Fiends' Are a New Southern Menace," portraying Black people who used cocaine as dangerous and able to withstand wounds that would normally be fatal. The Anti-Drug Abuse Act of 1986 mandated the same prison sentences for distributing 500 grams of powdered cocaine and just 5 grams of crack cocaine. In the National Survey on Drug Use and Health, white respondents reported a higher rate of powdered cocaine use, and Black respondents reported a higher rate of crack cocaine use.
== RCM Beynon Prize == To mark the 80th birthday of John H. Beynon, the founding Editor of RCM, in 2004 an annual award was established in his honour by the publishers. The award is made on the recommendation of an ad hoc Sub-committee of the editorial board of RCM.
== History == The therapeutic efficacy of subcutaneous pegcetacoplan in treating paroxysmal nocturnal hemoglobinuria has been established through several clinical trials. Initial phase I and II trials, such as PADDOCK, PALOMINO, and PHAROAH, evaluated pegcetacoplan in participants with paroxysmal nocturnal hemoglobinuria who had not received a complement inhibitor or had previously received eculizumab. These trials demonstrated that 1–2 years of pegcetacoplan treatment effectively controlled hemolysis and improved quality of life in participants with paroxysmal nocturnal hemoglobinuria. Building upon these findings, the efficacy of pegcetacoplan was further assessed in phase III trials. The PRINCE trial, a 26-week study, focused on complement inhibitor-naïve participants with paroxysmal nocturnal hemoglobinuria, while the PEGASUS trial, a 48-week multinational study, included complement inhibitor-treated participants with paroxysmal nocturnal hemoglobinuria. In these trials, subcutaneous pegcetacoplan was administered at a dosage of 1080 mg twice weekly, delivered as a 20-mL subcutaneous infusion. Participants had the option to self-administer the medication or have it administered by qualified research personnel.
=== March === 8 March The report of a 20-year survey by The Botanical Society of Britain and Ireland revealed that 56% of Ireland's native plant species are in decline due to habitat loss, altered grazing pressure, and degradation (re-seeding, over-fertilising, nitrogen deposition, herbicides, soil drainage, mineral enrichment), rather than rising temperatures whose botanical effects – so far – are minor. By contrast, 80% of non-native plants introduced into Ireland since 1500 have increased. The Taoiseach Leo Varadkar marked International Women's Day by announcing the Government's intention to hold a referendum to enshrine gender equality in the Constitution by amending Articles 40 and 41. 13 March – President of the United States Joe Biden announced that he will visit Ireland, north and south, in April for the 25th anniversary of the Good Friday Agreement (signed on 10 April 1998). It was reported two weeks later that Biden will arrive in Belfast on 11 April, then he will be based in Dublin from 12 to 15 April from where he will make trips to other parts of the country. Former US president Bill Clinton and his wife Hillary will visit Belfast the following week. 15 March – 46-year-old Stephen Silver was found guilty of the capital murder of Detective Garda Colm Horkan who was shot dead in Castlerea, County Roscommon in June 2020. 16 March – Ryan Tubridy announced that he would be stepping down as the presenter of The Late Late Show after 14 years, with his last show in May.
Sources: en.wikipedia.org
A break in the murder case of "Motamed" occurred when prosecutors got their hands-on text messages after they were able to unlock a decrypted cell phone from one of the participants in the plot. The two hitmen were discovered to have extensive criminal records and longstanding ties to organised crime. The text messages showed they were monitoring "Motamed", and had no clue why he was targeted, only that they were assigned with the task and were eager to get the job done. In April 2019, they were sentenced to 25 and 20 years of imprisonment for their roles in the murder. The messages also implicated "Noffel", who was found guilty for ordering the murder and sentenced to life in prison for his involvement in this hit. However, all three suspects remain silent about any of their involvement in this case. Dutch investigators were baffled when it became clear that the killers of "Motamed" were working on the orders of the Dutch-Moroccan crime boss "Noffel", a close associate of Ridouan Taghi. The Dutch government sees "Motamed" as the link between Taghi and the Iranian secret service. However, the execution of Mohammad-Reza Kolahi ("Ali Motamed") was not the only murder in which the Dutch government accuses Iran of being involved in. In 2017, an assassin shot several bullets into Ahmad Mola Nissi, the leader of the Iranian separatist group Arab Struggle Movement for the Liberation of Ahwaz. Nissi died in front of his house in The Hague, after living in the Netherlands for over a decade.
Opioid peptides are classified based on their larger precursor propeptide: all endorphins are synthesized from the precursor proopiomelanocortin (POMC), enkephalins from proenkephalin, and dynorphins and neoendorphins from prodynorphin.
== Function == Xaa-Pro dipeptidase is a cytosolic dipeptidase that hydrolyzes dipeptides with proline or hydroxyproline at the carboxy terminus (but not Pro-Pro). It is important in collagen metabolism because of the high levels of imino acids. Mutations at the PEPD locus cause prolidase deficiency. This is characterised by Iminodipeptidurea, skin ulcers, mental retardation and recurrent infections. Serum prolidase falls into the category of proteases, specifically exopeptidases. These EC numbers range from 3.4.11 to 3.4.19.
Atomoxetine, sold under the brand name Strattera, is a selective norepinephrine reuptake inhibitor (SNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) and, to a lesser extent, cognitive disengagement syndrome (CDS). It may be used alone or along with psychostimulant medication. It enhances the executive functions of self-motivation, sustained attention, inhibition, working memory, reaction time, and emotional self-regulation. Use of atomoxetine is only recommended for those who are at least six years old. It is taken orally. The effectiveness of atomoxetine is comparable to the commonly prescribed stimulant medication methylphenidate. Common side effects of atomoxetine include abdominal pain, decreased appetite, nausea, feeling tired, and dizziness. Serious side effects may include angioedema, liver problems, stroke, psychosis, heart problems, suicide, and aggression. There is a lack of data regarding its safety during pregnancy; as of 2019, its safety during pregnancy and for use during breastfeeding is not certain. It was approved for medical use in the United States in 2002. In 2023, it was the 161st most commonly prescribed medication in the United States, with more than 3 million prescriptions.
LRP1 (Low-Density Lipoprotein Receptor-Related Protein 1): LRP1 is involved in the endocytosis and degradation of various ligands, including AGEs. It is expressed in tissues such as the liver, vascular smooth muscle cells, and neurons. LRP1 functions by promoting the cellular uptake of AGE-modified proteins, thereby preventing their accumulation and reducing oxidative damage. The receptor also interacts with signaling pathways that regulate inflammation, making it an important factor in protecting against AGE-induced vascular and metabolic complications. MSR1 (Macrophage Scavenger Receptor 1): MSR1, also known as class A scavenger receptor, is expressed primarily on macrophages and plays a crucial role in the phagocytic uptake of AGEs. By recognizing and internalizing AGE-modified proteins, MSR1 helps reduce inflammation and cellular stress in tissues exposed to AGEs. This receptor is involved in activating pro-inflammatory signaling pathways, but it also contributes to tissue repair and the resolution of inflammation, helping maintain tissue homeostasis. FEEL-1/CLEC14A (Facultative Endothelial Lectin-1): FEEL-1, also known as CLEC14A, is a C-type lectin receptor expressed on endothelial cells. It binds AGEs and facilitates their clearance, thereby helping to maintain vascular health. The interaction of FEEL-1 with AGEs is thought to reduce endothelial cell activation and inflammation, contributing to the protection of blood vessels from AGE-induced damage and maintaining vascular integrity.
Sources: en.wikipedia.org
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.
It describes the share of the chromatographic signal belonging to the main peak, not the mass fraction of peptide in the vial. Water, counter-ions such as acetate or trifluoroacetate, and residual solvents account for part of the weight of a lyophilized lot. Peptide content by mass is a separate measurement and is often reported alongside purity.
Mass spectrometry is the primary check, because the measured mass can be compared with the expected value for the fifteen-residue chain. Sequence analysis or amino acid composition provides an independent confirmation. Purity testing alone does not establish identity, since a mixture of unrelated short peptides can still produce a clean-looking chromatogram.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.